NASDAQ: MTVAMetavia Inc Stock
$0.65-0.01 (-1.52%)
Updated Jul 3, 2025
MTVA Price
$0.65
Fair Value Price
N/A
Market Cap
$12.68M
52 Week Low
$0.63
52 Week High
$5.16
P/E
-0.21x
P/B
2.89x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.55M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.77
Operating Cash Flow
-$23M
Beta
0.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MTVA Overview
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MTVA's potential to beat the market
- MTVA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MTVA
RankedUnranked of 468
RankedUnranked of 468
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.59 | A | |
| $3.58 | A | |
| $46.15 | A |
Be the first to know about important MTVA news, forecast changes, insider trades & much more!
MTVA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MTVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MTVA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MTVA is good value based on its book value relative to its share price (2.89x), compared to the US Biotechnology industry average (4.54x)
P/B vs Industry Valuation
MTVA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MTVA due diligence checks available for Premium users.
Valuation
MTVA fair value
Fair Value of MTVA stock based on Discounted Cash Flow (DCF)
Price
$0.65
Fair Value
$2.05
Undervalued by
68.25%
MTVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MTVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.21x
Industry
-154.26x
Market
30.96x
MTVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.89x
Industry
4.54x
MTVA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MTVA's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.7M
Profit Margin
0%
MTVA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.1M
Liabilities
$7.7M
Debt to equity
1.77
MTVA's short-term assets ($11.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MTVA's short-term assets ($11.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MTVA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MTVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
$0.0
Financing
-$12.0k
MTVA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MTVA vs Biotech Stocks
Metavia Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.